Advertisement
Genetic variations have been identified in the ERG gene that are associated with an increased risk for acute lymphoblastic leukemia in Hispanic children

Genetic Variant Tied to Leukemia Risk in Hispanic Children

0
Novel susceptibility locus identified in the ERG gene for acute lymphoblastic leukemia
Single-application fecal immunochemical tests have moderate-to-high sensitivity and specificity for colorectal cancer

Single-Application FIT Moderately Sensitive, Specific for CRC

0
Performance characteristics vary depending on the threshold for a positive result
Despite claims to the contrary

FDA: Thermography No Substitute for Mammograms

0
Agency is taking action to stop false advertising about thermography
In the absence of further intervention

44.4 Million Estimated to Be Diagnosed With Cervical Cancer by 2069

0
From 2020 to 2069, 6.7 to 7.7 million cases could be averted by scaling up HPV vaccination by 2020
Just one-third of users of biologically based complementary medicine disclose their use to traditional health care providers

Most Patients Do Not Disclose Complementary Medicine Use

0
Lack of inquiry from providers, fear of disapproval, belief CM is safe among reasons for nondisclosure
National health spending is projected to increase at an annual rate of 5.5. percent from 2018 to 2027

National Health Spending Set to Increase 5.5 Percent Annually

0
Long-observed demographic and economic factors expected to drive growth in health spending
One-third of primary care providers report participating in breast cancer treatment decisions

One-Third of PCPs Discuss Breast Cancer Treatments With Patients

0
However, many report feeling uncomfortable or believing they lack the necessary knowledge
Vertical integration between hospitals and physicians has little impact on quality measures

Vertical Integration Has Little Impact on Quality Measures

0
Increased hospital market concentration tied to reduced quality in patient satisfaction measures
An antibody-drug conjugate

Sacituzumab Govitecan Promising in Triple-Negative Breast Cancer

0
Response rate of 33.3 percent, median response duration of 7.7 months observed in 108 patients
In high-risk ambulatory patients with cancer

Rivaroxaban Does Not Reduce VTE Incidence in High-Risk Cancer Patients

0
Primary end point occurred in lower percentage of patients in 180-day period; difference not significant